In addition to our prior findings on targeting Rab18 prenylation with statins, this study highlights MAPK signaling components as potential therapeutic targets to mitigate the pro-migratory side effects of 2′3′-cGAMP, thereby improving the safety profile of cGAS/STING agonists as cancer immunotherapeutics. The gene discussed is RAB18; the disease is cancer.